To ensure the reliability of our findings and avoid masking potential benefits on Hb levels, we specifically targeted patients with stable PTH levels corresponding to their CKD stage, maintaining a balanced calcium-phosphate ratio without any signs of inflammation. The gene discussed is PTH; the disease is chronic kidney disease.